Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to define whether combination of induction chemotherapy and PD-1
inhibitor (Toripalimab) improve the rate of larynx preservation, for patients with resectable
laryngeal/hypopharyngeal carcinoma.